A phase III randomized, open-label, controlled trial of chemotherapy and bevacizumab with or without panitumumab in the first-line treatment of patients with metastatic colorectal cancer

Clinical Colorectal Cancer

Volumn 5, Issue 5, 2006, Pages 363-367

  Wainberg, Zev ^a   Hecht, J Randolph ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

5 Fluorouracil; Epidermal growth factor receptor; Irinotecan; Leucovorin; Oxaliplatin; Vascular endothelial growth factor

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; MATUZUMAB; OXALIPLATIN; PANITUMUMAB; PROTEIN TYROSINE KINASE INHIBITOR; TRANSFORMING GROWTH FACTOR ALPHA;

ACNE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG POTENTIATION; DRUG TOLERABILITY; ENZYME INHIBITION; FOOD AND DRUG ADMINISTRATION; HUMAN; INTERSTITIAL LUNG DISEASE; MACULOPAPULAR RASH; METASTASIS; OPEN STUDY; RANDOMIZATION; STATISTICAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33244473097     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2006.n.008     Document Type: Article

References (25)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005 [published erratum in CA Cancer J Clin 2005;55:259]. CA Cancer J Clin 2005; 55:10-30.
2. Saltz LB, Cox DO, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000; 343:905-914.
3. Rothenberg ML, Oza AM, Gegelo R, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003; 21:2059-2069.
4. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX or the reverse sequence in advanced colorectal cancer. J Clin Oncol 2004; 22:229-237.
5. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2334-2342.
6. Kabbinavar FF, Hurwitz H, Fehrenbacher L, et al. Phase II randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2004; 21:60-65.
7. Hochster HS, Welles L, Hart L, et al. Safety and efficacy of bevacizumab (Bev) when added to oxaliplatin/fluoropyrimidine (O/F) regimens as first-line treatment of metastatic colorectal cancer (mCRC): TREE 1 & 2 studies. J Clin Oncol 2005; 23(suppl 16):249s (Abstract #3515).
8. Giantonio BJ, Catalano PJ, Meropol NJ, et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J Clin Oncol 2005; 23(suppl 16): 1s (Abstract #2).
9. Real FX, Rettig WJ, Chesa PG, et al. Expression of epidermal growth factor receptor in human cultured cells and tissues: relationship to cell lineage and stage of differentiation. Cancer Res 1986; 46:4726-4731.
10. Yasui W, Sumiyoshi H, Hata J, et al. Expression of epidermal growth factor receptor in human gastric and colonic carcinomas. Cancer Res 1988; 48:137-141.
11. Yarden Y, Sliwkowski MX Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2:127-137.
12. Yokoi K, Thaker PH, Yazici S, et al. Inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model. Cancer Res 2005; 65:3716-3725.
13. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-345.
14. Saltz LB, Meropol NJ, Lochrer PJ Sr, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22:1201-1208.
15. Tabernero JM, Van Cutsem E, Sastre J, et al. An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/ folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing epidermal growth factor receptor (EGFR). Preliminary results. Proc Am Soc Clin Oncol 2004; 23:248 (Abstract #3512).
16. Rougier P, Raoul JL, et al. Cetuximab+FOLFIRI as first-line treatment for metastatic colorectal cancer CA. Proc Am Soc Clin Oncol 2004; 23:248 (Abstract #3513).
17. TM [package insert]. Branchburg, NJ/Princeton, NJ: ImClone Systems Inc/Bristol-Myers-Squibb; 2005.
18. Lynch DH, Yang XD. Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin Oncol 2002; 29:47-506.
19. Figlin RA, Belldegrun AS, Crawford J, et al. ABX-EGF, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) in patients with advanced cancer: phase 1 clinical results. Proc Am Soc Clin Oncol 2002; 21: 10a (Abstract #35).
20. Malik I, Hecht JR, Patnaik A, et al. Safety and Efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC). J Clin Oncol 2005; 23(suppl 16):251s (Abstract #3520).
21. Weiner LM, Belldegrun A, Rowinsky E, et al. Updated results from a dose and schedule study of panitumumab (ABX-EGF) monotherapy in patients with advanced solid malignancies. J Clin Oncol 2005; 23(suppl 16):206s (Abstract #3059).
22. Berlin J, Malik I, Piens J, et al. Panitumumab therapy with irinotecan, 5-FU and leucovorin in patients with metastatic colorectal cancer. Presented at: the 9th Annual Meeting of the European Society for Medical Oncology; October 29-November 2, 2004; Vienna, Austria.
23. Starling N, Cunningham D. Monoclonal antibodies against vascular endothelial growth factor and epidermal growth factor receptor in advanced colorectal cancers: present and future directions. Curr Opin Oncol 2004; 16:385-390.
24. Saltz L, Lenz H, Kindler HL, et al. Interim report of randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/ bevacizumab (CB) in irinotecan-refractory colorectal cancer. Presented at: the American Society of Clinical Oncology 2005 Gastrointestinal Cancers Symposium; January 27-29, 2005; Hollywood, Florida. Abstract #169b.
25. Cohen R, Falcey J, Paulter V, et al. Safety profile of the monoclonal antibody (MoAb) IMC-C225, and anti-epidermal growth factor receptor (EGFR) used in the treatment of EGFR-positive tumors. Proc Am Soc Clin Oncol 2000; 19:474a (Abstract #1862).